JP2017523796A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523796A5
JP2017523796A5 JP2017506955A JP2017506955A JP2017523796A5 JP 2017523796 A5 JP2017523796 A5 JP 2017523796A5 JP 2017506955 A JP2017506955 A JP 2017506955A JP 2017506955 A JP2017506955 A JP 2017506955A JP 2017523796 A5 JP2017523796 A5 JP 2017523796A5
Authority
JP
Japan
Prior art keywords
seq
following sequence
encephalitis virus
structural protein
equine encephalitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506955A
Other languages
English (en)
Japanese (ja)
Other versions
JP6824154B2 (ja
JP2017523796A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/003997 external-priority patent/WO2016021209A1/en
Publication of JP2017523796A publication Critical patent/JP2017523796A/ja
Publication of JP2017523796A5 publication Critical patent/JP2017523796A5/ja
Application granted granted Critical
Publication of JP6824154B2 publication Critical patent/JP6824154B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506955A 2014-08-08 2015-08-07 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子 Active JP6824154B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201462035037P 2014-08-08 2014-08-08
US62/035,037 2014-08-08
US201462079128P 2014-11-13 2014-11-13
US62/079,128 2014-11-13
US201562101514P 2015-01-09 2015-01-09
US62/101,514 2015-01-09
US201562120569P 2015-02-25 2015-02-25
US62/120,569 2015-02-25
US201562198949P 2015-07-30 2015-07-30
US62/198,949 2015-07-30
PCT/JP2015/003997 WO2016021209A1 (en) 2014-08-08 2015-08-07 Virus like particle comprising modified envelope protein e3

Publications (3)

Publication Number Publication Date
JP2017523796A JP2017523796A (ja) 2017-08-24
JP2017523796A5 true JP2017523796A5 (enExample) 2018-09-06
JP6824154B2 JP6824154B2 (ja) 2021-02-03

Family

ID=55263499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506955A Active JP6824154B2 (ja) 2014-08-08 2015-08-07 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子

Country Status (6)

Country Link
US (1) US9969986B2 (enExample)
EP (1) EP3177720B1 (enExample)
JP (1) JP6824154B2 (enExample)
CN (1) CN106795513B (enExample)
TW (1) TWI720946B (enExample)
WO (1) WO2016021209A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX357202B (es) 2012-02-16 2018-06-28 Vlp Therapeutics Llc Composicion de particula tipo virus.
SG11201509614SA (en) 2013-06-03 2015-12-30 Vlp Therapeutics Llc Malaria vaccine
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
CA2960102C (en) 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
BR112017014219A2 (en) 2014-12-31 2018-03-06 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services multivalent nanoparticle-based vaccines
US10166281B2 (en) 2015-09-04 2019-01-01 Vlp Therapeutics, Llc Method and composition for modulating immune response
WO2017150683A1 (en) * 2016-03-04 2017-09-08 Vlp Therapeutics, Llc Zika virus virus like particle
WO2017221076A1 (en) * 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
CN110167585B (zh) 2016-09-02 2024-03-08 美国卫生与公众服务部 稳定化的第2组流感血凝素茎区三聚体及其用途
EP3600406A4 (en) 2017-03-28 2021-01-13 Children's Hospital Medical Center VLP-BASED BIVALENT EBOLA VACCINES AND METHOD FOR MANUFACTURING AND USING THEREOF
CN110636855B (zh) 2017-03-28 2024-08-09 俄亥俄州创新基金会 人pd1肽疫苗及其用途
KR102823029B1 (ko) * 2017-12-20 2025-06-20 브이엘피 테라퓨틱스 인코포레이티드 알파바이러스 레플리콘 입자
JP2021512966A (ja) * 2018-02-07 2021-05-20 イミュジーン、リミテッドＩｍｕｇｅｎｅ Ｌｉｍｉｔｅｄ ワクチン組成物およびその使用
WO2019156223A1 (ja) * 2018-02-09 2019-08-15 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
FR3078535B1 (fr) * 2018-03-05 2024-02-09 Peptinov Sas Composition vaccinale anti-pd-l1
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
TWI891771B (zh) 2020-04-17 2025-08-01 美商Ｖｌｐ醫療股份有限公司 冠狀病毒疫苗
MX2022013638A (es) 2020-04-30 2023-01-24 Vlp Therapeutics Inc Inmunoterapia con citocina.
EP4326858A4 (en) * 2021-04-23 2025-03-12 VLP Therapeutics, Inc. GALECTIN-TARGETED IMMUNOTHERAPY
CN115466330B (zh) * 2021-06-10 2023-10-20 清华大学 一种基于病毒样颗粒呈递冠状病毒受体结合区的冠状病毒亚单位疫苗
EP4377449A1 (en) * 2021-07-26 2024-06-05 Beam Therapeutics, Inc. Pseudotyped recombinant lyssaviruses for gene therapy
JP2025513920A (ja) * 2022-04-18 2025-04-30 Ｃｙｎ－Ｋバイオ株式会社 炎症性疾患の処置
CN116042657A (zh) * 2023-01-16 2023-05-02 上海复诺健生物科技有限公司 自复制信使核糖核酸疫苗
WO2025084276A1 (ja) * 2023-10-16 2025-04-24 Ｃｙｎ－Ｋバイオ株式会社 肥満の処置

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
JP3954643B2 (ja) 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質
US5580773A (en) 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
CA2232669A1 (en) 1995-09-27 1997-04-03 Frances Joanne Morling Recombinant viruses incorporating a protease cleavable protein
CA2320958A1 (en) 1998-02-11 1999-08-19 Maxygen, Inc. Antigen library immunization
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
CA2448908C (en) 2001-05-30 2008-03-18 Transgene S.A. Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
WO2004043399A2 (en) 2002-11-13 2004-05-27 The United States Of America As Represented By The Secretary Of The Navy Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
MXPA05012754A (es) * 2003-05-29 2006-05-17 Army Medical Res Inst For I Vacunas virales atenuadas vivas para virus de encefalitis equina oriental.
CA2547511A1 (en) 2003-12-01 2005-07-28 Dow Global Technolgies Inc. Recombinant icosahedral virus like particle production in pseudomonads
BRPI0518146A (pt) 2004-10-14 2008-10-28 Crucell Holland Bv kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
WO2006088229A1 (ja) 2005-02-16 2006-08-24 The Circle For The Promotion Of Science And Engineering 改変されたウイルスカプシドタンパク質及びその使用
DK1907000T4 (da) 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
EP2889309B1 (en) 2006-03-03 2017-12-27 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of pd-1 or pd-l1
AU2007291936B2 (en) 2006-08-30 2012-09-27 Artes Biotechnology Gmbh Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
WO2009079185A2 (en) 2007-11-26 2009-06-25 Novartis Vaccines And Diagnostics, Inc. Methods of generating alphavirus particles
CN102317308A (zh) * 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
ES2987238T3 (es) * 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
WO2011035004A1 (en) 2009-09-18 2011-03-24 Fraunhofer Usa Inc. Virus like particles comprising target proteins fused to plant viral coat proteins
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
WO2012023995A1 (en) 2010-08-18 2012-02-23 Takayuki Shiratsuchi Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes
WO2012106356A2 (en) 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
CN103796676B (zh) 2011-06-17 2017-09-12 伯哈拉特生物技术国际有限公司 包含灭活的基孔肯亚病毒株的疫苗组合物
CN102321639B (zh) 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 基孔肯雅病毒病毒样颗粒的制备方法和应用
PH12014500911A1 (en) 2011-10-25 2014-06-09 Florida Gulf Coast Univ Board Of Trustees Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
MX357202B (es) * 2012-02-16 2018-06-28 Vlp Therapeutics Llc Composicion de particula tipo virus.
EP2834265A4 (en) 2012-04-02 2015-10-14 Univ North Carolina METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
SG11201509614SA (en) 2013-06-03 2015-12-30 Vlp Therapeutics Llc Malaria vaccine
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
WO2015139784A1 (en) 2014-03-18 2015-09-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
US9363353B1 (en) 2014-12-04 2016-06-07 Hon Man Ashley Chik Mobile phone docks with multiple circulating phone connectors
BR112017014219A2 (en) * 2014-12-31 2018-03-06 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services multivalent nanoparticle-based vaccines
JPWO2016199936A1 (ja) 2015-06-12 2018-04-05 国立大学法人三重大学 ヒトパラインフルエンザ２型ウイルスベクター及びワクチン
US10799575B2 (en) 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)
CA2992531C (en) 2015-07-16 2023-09-26 Bharat Biotech International Limited Vaccine compositions
MA42502A (fr) 2015-07-21 2018-05-30 Modernatx Inc Vaccins contre une maladie infectieuse
CN106085974B (zh) 2016-06-07 2019-08-09 博奥生物集团有限公司 一种寨卡病毒假病毒颗粒及其制备方法

Similar Documents

Publication Publication Date Title
SG11202003746UA (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
ZA202002249B (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
JP2019194236A5 (enExample)
JP2017048194A5 (enExample)
JP2018024670A5 (enExample)
JP2017514877A5 (enExample)
JP2018030858A5 (enExample)
EA201790630A1 (ru) Способы получения рибозидов
LT3577124T (lt) Nukleotido hemisulfato druska, skirta hepatito c virusui gydyti
ZA202101615B (en) African swine fever virus vaccine
EP4659816A3 (en) MODIFIED CAPSID PROTEINS FOR IMPROVED PARVOVIRUS VECTOR DELIVERY
JP2016525888A5 (enExample)
JP2019524645A5 (enExample)
JP2016153424A5 (enExample)
JP2017186358A5 (enExample)
JP2017532302A5 (enExample)
EA201890527A1 (ru) Терапевтические вакцины против hpv18
JP2011527560A5 (enExample)
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
JP2014028813A5 (enExample)
LT3512863T (lt) 2'-pakeistieji-n6-pakeistieji purino nukleotidai, skirti gydymui rnr virusu
EP3148566C0 (en) LONG SYNTHETIC PEPTIDES (SLP) FOR THERAPEUTIC VACCINATION PURPOSES AGAINST HEPATITIS B VIRUS INFECTION
JP2017501211A5 (enExample)
JP2018116258A5 (enExample)
HUE052833T2 (hu) Eljárás 2,5-furándikarbonsav (FDCA) elõállítására